ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effects of Chromium Picolinate on Food Intake

This study has been completed.

Sponsored by: Pennington Biomedical Research Center
Information provided by: Pennington Biomedical Research Center
ClinicalTrials.gov Identifier: NCT00477854
  Purpose

The purpose of this study is to test the effects of chromium picolinate on food intake, food cravings, eating attitudes, and appetite. If chromium picolinate is found to have a beneficial impact on satiety and food intake, then this supplement may be an alternative or adjunctive treatment for overweight people desiring to modify their food intake. The primary hypothesis of this study is that among individuals who report being carbohydrate cravers, chromium picolinate supplementation will reduce food intake during a test lunch meal and produce greater satiety in comparison to a placebo.


Condition Intervention
Obesity
Atypical Depression
Drug: Chromium Picolinate

MedlinePlus related topics:   Depression    Obesity   

ChemIDplus related topics:   Chromium    Chromium picolinate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment

Further study details as provided by Pennington Biomedical Research Center:

Primary Outcome Measures:
  • Food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • Hunger and satiety between the lunch and dinner meal [ Time Frame: 8 weeks ]

  Eligibility
Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

Inclusion criteria are:

  1. Healthy female who has not been diagnosed with diabetes, cardiovascular illness, or other chronic diseases,
  2. Food craver, determined by self-reported craving for carbohydrates on two out of three validated measures of food cravings,
  3. > 18 years of age and < 50 years of age, and
  4. Body mass index between 25 and 39.9 kg/m2. Participants will be scheduled for testing during the luteal phase of their menstrual cycle to limit the confounding effect of the menstrual cycle on energy intake. We will include women who are taking monophasic oral contraceptives but will exclude other oral contraceptive regimens. Participants with very irregular menstrual cycles will also be excluded because this irregularity will make it very difficult to schedule testing during the luteal phase of the menstrual cycle.

Exclusion Criteria:

Potential participants will be excluded for the following reasons:

  1. Participants who report smoking cigarettes will be excluded because of the effects of nicotine upon taste and appetite,
  2. Participants who have a diagnosable eating disorder (i.e., anorexia or bulimia nervosa) will also be excluded since intentional restriction of eating and binge eating/overeating could increase the variability of the data,
  3. Participants who report using diet pills will be excluded since diet pills may potentially influence appetite, hunger, and/or satiety,
  4. Participants will be excluded if they are taking anti-depressant medications, anti-psychotic medications, or any medications that may potentially influence appetite, hunger, and/or satiety,
  5. Participants who are not determined to be carbohydrate cravers will be excluded,
  6. Participants will also be excluded if they report any allergies to the foods that will be used in the study.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00477854

Locations
United States, Louisiana
Pennington Biomedical Research Center    
      Baton Rouge, Louisiana, United States, 70808

Sponsors and Collaborators
Pennington Biomedical Research Center

Investigators
Principal Investigator:     Stephen D Anton, Ph.D.     Pennington Biomedical Research Center    
  More Information


Study ID Numbers:   24040
First Received:   May 23, 2007
Last Updated:   May 23, 2007
ClinicalTrials.gov Identifier:   NCT00477854
Health Authority:   United States: Institutional Review Board

Study placed in the following topic categories:
Body Weight
Signs and Symptoms
Obesity
Depression
Chromium
Picolinic acid
Nutrition Disorders
Overweight
Overnutrition
Depressive Disorder
Iron
Behavioral Symptoms

Additional relevant MeSH terms:
Molecular Mechanisms of Pharmacological Action
Growth Substances
Physiological Effects of Drugs
Iron Chelating Agents
Trace Elements
Chelating Agents
Micronutrients
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers